Organisation paid for research Program year 2025 Source: CMS Open Payments

Childrens Hospital

Neither a doctor nor a teaching hospital

Research payments

$724,892

322 payments

Through program year 2025, Childrens Hospital is reported as receiving $724,892 in research payments, across 322 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $15,938 7
2024 Research $14,152 288
2023 Research $30,802 14
2022 Research $662,615 10
2021 Research $1,385 3

Breakdown

Who paid Research payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $668,546 14 payments
  2. Novo Nordisk AS $21,855 292 payments
  3. Teva Pharmaceuticals USA, Inc. $16,000 4 payments
  4. Sumitomo Pharma America, Inc. $8,235 3 payments
  5. Ge Healthcare $4,548 3 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,750 1 payment
  7. Eli Lilly and Company $1,125 1 payment
  8. Pfizer Inc. $820 3 payments
  9. Medtronic, Inc. $13 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab With Or Without Hydroxyurea Hydroxycarbamide in Sequential Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso Occlusive Cris $242,017 1 payment
  2. Phase II Open Label Global Study to Evaluate the Effect of Dabrafenib Treatment in Children and Adolescent Subjects With Braf V600 Mutation Positive Relapsed Refractory Or Progressive HGG Tumor $215,884 2 payments
  3. An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) And/Or Mekinist (Trametinib) $169,713 1 payment
  4. An Open-Label, Multi-Center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed A Prior Novartis-Sponsored Crizanlizumab Study $19,141 1 payment
  5. Nn7415-4807 $18,480 291 payments
  6. An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) $16,000 4 payments
  7. Two Part (Double-Blind Inclisiran Versus Placebo [Year 1] Followed By Open-Label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Fam $11,739 1 payment
  8. A Multicenter Study to Evaluate Safety and Tolerability of Open Label Lcz696 in Pediatric Heart Failure Patients Who Have Successfully Completed the Panorama HF Study A $9,723 3 payments
  9. A Phase 2/3, Open-Label, Baseline-Controlled, Multicenter, Long-Term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (Ndo) on Clean Intermittent Catheterization (Cic) $8,235 3 payments
  10. A Phase 3B Multicenter Open-Label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (Arpkd) $3,750 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record